We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-15.93%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$307M
AUM Growth
-$111M
Cap. Flow
-$25.2M
Cap. Flow %
-8.21%
Top 10 Hldgs %
66.99%
Holding
55
New
8
Increased
13
Reduced
15
Closed
15

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$26.3M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$16.1M
3
OCUL icon
Ocular Therapeutix
OCUL
+$2.82M
4
IGMS
IGM Biosciences
IGMS
+$1.68M
5
GOSS icon
Gossamer Bio
GOSS
+$1.6M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.79M
2
TELA icon
TELA Bio
TELA
+$7.71M
3
CBAY
Cymabay Therapeutics
CBAY
+$6.21M
4
TBPH icon
Theravance Biopharma
TBPH
+$5.63M
5
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$5.57M

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
2 Miscellaneous 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBPH icon
51
Theravance Biopharma
TBPH
$885M
– –
-543,500
Closed -$5.63M
CBAY
52
DELISTED
Cymabay Therapeutics
CBAY
– –
-566,700
Closed -$6.21M
THRX
53
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-597,500
Closed -$5.57M
JNCE
54
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-669,944
Closed -$918K
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2023 Portfolio in Review

As of Q3 2023, Opaleye Management held 55 positions worth $307M, down 26% from $418M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Opaleye Management withdrew a net $25.2M in Q3 2023, closing 15 positions and reducing 15 holdings. Its most notable exit was Cymabay Therapeutics, an estimated $6.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in TG Therapeutics worth $15.8M.

  • Opaleye Management's largest Q3 2023 buy was TG Therapeutics: 1,890,000 shares worth $15.8M.
  • Opaleye Management added most to Ocular Therapeutix in Q3 2023, an estimated $2.82M increase.
  • Opaleye Management's biggest Q3 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $9.79M.
  • Opaleye Management fully exited Cymabay Therapeutics in Q3 2023, selling an estimated $6.21M.
  • Opaleye Management's ten largest holdings make up 67% of its $307M portfolio in Q3 2023.
  • Opaleye Management opened 8 new positions and closed 15 in Q3 2023.
  • Opaleye Management's portfolio value fell 26% quarter-over-quarter to $307M.

Based on Opaleye Management's 13F filing for Q3 2023, filed 15 Nov 2023.